ew outperform expect everi metric tavr franchis strength lead
way improv outlook see posit ww tavr trend driven
increas capac low risk creep valve-in-valv volum ramp deeper penetr
intermedi risk indic front low risk approv reiter
outperform increas price target
tavr grew double-digit everi region driven strong therapi adopt
also remain stabl manag estim tavr growth
in-lin broader procedur growth quarter tavr out-performance
attribut better expect therapi adopt particularli lower volum
center absenc expect season geograph basi ou tavr
busi also grew double-digit procedur growth europ growth
countri lower adopt outpac market greater adopt japan
qualifi fastest grow region intern despit increas level
confid thvt growth guidanc manag note
contempl contribut low-risk patient front data
expect even high end guidanc rang expect
hit take account strong outlook manag still believ tavr
market opportun see tavr perform combin
posit guidanc revis top end rang
enough sustain recent stock momentum
compani increas full-year sale estim higher end prior
guidanc attribut half revis sale momentum
mostli thvt half foreign exchang specif ew believ
experi upper-end sale growth three busi divis thvt
move attribut underli strength two divis benefit
foreign exchang remind decemb compani initi target
transcathet heart valv therapi reflect underli growth
includ roughli million tmtt product sale also set rang
surgic heart valv sale project critic care sale
ask thursday earn call whether favor
adjust thvt outlook stem revis view rel share
market dynam overal manag indic expect continu fast adopt
within market hasnt bake share gain assumpt outlook
like prove conserv view ew simultan rais full-year adjust
ep rang previous chang
driven lower expect tax rate vs previous along higher
project oper perform two item compani say affect revis
pleas see page report import disclosur
base outperform rate belief sustain ew high-single-digit
double-digit top-lin growth along double-digit ep growth trajectori driver
compani includ tavr market leadership age global elderli popul shift
aortic stenosi risk curv tavr rais tavr awar among patient
expect last year fda ce mark approv sapien intermedi risk aid
upsid trial prove favor believ ew share continu valu
premium median forward price-to-earnings multipl compani large-cap peer churn
centera sapien ultra ce launch
intermedi risk market develop
wake surtavi data readout
updat mitral program timelin
maintain market share
top-lin growth acceler
us tavr market
top-lin growth deceler
strong adopt sapien high-risk/
ew mitral program develop faster
expect
inoper patient us
continu success roll-out sapien
intermedi risk
ew lead medic devic compani manufactur heart valv repair
product replac repair diseas defect heart compani also provid
hemodynam monitor system cardiovascular function measur hospit
set headquart irvin california ew oper roughli countri
employe world-wide compani found edward
laboratori acquir baxter spun baxter earli
ew sale product world-wide posit
promis product pipelin updat support longev top-lin success
new technolog front ew continu anticip receiv ce mark approv
centera system month ultra quarter compani market
centera premium-pr self-expand system move believ justifi given
devic feature-rich design price europ self-expand valv system
roughli lower ew think centera price closer
self-expand peer confer call thursday ew said centera
label would like vari slightli countri countri compani intend bring
centera later year via trial respect ultra devic
mani advanc featur simplifi procedur potenti reduc risk
complic also taller outer skirt valv design
improv perform ew said obvious pleas perform
think ultra may take contribut next level compani expect devic
approv unit state late importantli ew guidanc assum
littl either centera ultra clinic front ew complet enrol
main studi trial low-risk patient compani expect data
studi receiv fda approv later also enrol
early-tavr trial evalu sever aortic stenosi patient without diagnos
mitral repair portfolio highlight cardioband pascal harpoon
three option bring differenti valu proposit surgeon patient
cardioband meant address patient annular dilat pascal aim
need leaflet repair harpoon target patient need chord repair
ew continu enrol patient activ trial cardioband product
alreadi ce mark europ expect contribut sale pascal
current ce mark trial stage anticip complet date
clasp ce mark trial eu launch trial start date sell
point pascal intuit use enabl rapid adopt heart team
broad applic across rang mr ew recent receiv ce mark harpoon
expect european launch midyear cardiaq sapien repres ew
two mitral replac program first-inhuman/earli feasibl studi way
ultim goal system reduc mr zero use safe transsept
procedur accomplish manag believ would significantli expand treatment
leverag ew sapien platform includ dock devic enabl improv
disappoint top bottom line come ahead street
ew post stellar beat across board report revenu
consensu estim ep vs consensu
out-performance also consist across busi unit transcathet revenu
vs consensu surgic heart valu therapi revenu vs
consensu critic revenu street
 thvt growth yoy driven excel adopt across
tavr center sapien valv continu demonstr strong outcom shvt
growth larg part function strong aortic valv sale across region well
new product driven share gain critic strong across product categori
especi china gross margin slightli consensu
estim compar favor yoy comp favor
profit mix partial off-set previous announc manufactur plant closur
increas price target given stronger forecast ew
 tavr unit posit guidanc revis pt partial base dcf
analysi valu edward base savr critic tavr busi new pt
impli adjust ep estim signific premium median multipl
larg cap medic devic peer exclud ew remain optimist
intermedi risk indic low risk creep valve-in-valv extend
market tail front contribut low risk mitral tricuspid opportun
believ stock momentum sustain continu strong ww trend
posit updat mitral tricuspid program low risk trial
enrol complet data expect
enhanc investor sentiment given backdrop ew uniqu sustain strong
figur edward lifesci result vs cowen estim consensu
compani report thomson eikon cowen compani
chg chg chgestim heart heart good gross gross margin oper net interest expens net expens pre-tax incom tax incom tax net incom dilut share estimatesactu cowen
compani report thomson eikon cowen compani
good basic share mm dilut share tax forma net forma ep incl net ep analysisgross analysistot forma cowen
compani report thomson eikon cowen compani
compani report thomson eikon cowen compani
usecent tavr enu cardioband enu total enu growth tavr enu growth cardioband growth trial/hd usequarterli clinic trial usecent commerci total commerci growth total enu growth q/q enu growth q/q non-royalti enu growth q/q pure commerci enu growth usecent commerci total worldcommerci usecent world ww enu cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
continu util pressur account organ play bigger
role health care deliveri competit dynam global potenti regulatori delay
reject failur devic clinic trial econom sensit price pressur
and/or weaken consum demand develop market econom and/or polit
uncertainti emerg market intellectu properti challeng
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken demand develop market econom
and/or polit uncertainti emerg market setback develop tmvr
product prevent commerci fluctuat foreign exchang rate
